Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points

Loxo Oncology $LOXO and Blueprint Medicines $BPMC have been duking it out with their early-stage studies on their RET inhibitors, and they were both back at it with updates for mutant medullary thyroid cancer at the American Thyroid Association meeting over the weekend.